The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials
The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials
Objective: People with mood disorders have increased risk of comorbid medical diseases versus the general population. It is paramount to identify interventions to improve physical health in this population. Methods: Umbrella review of meta-analyses of randomised controlled trials (RCTs) on pharmacological/non-pharmacological interventions for physical health outcomes/intolerability-related discontinuation in mood disorders (any age). Results: Ninety-seven meta-analyses were included. Among youths, against placebo, in depression, antidepressants/antipsychotics had higher discontinuation rates; in bipolar depression, olanzapine+fluoxetine worsened total cholesterol (TC)/triglycerides/weight gain (WG) (large ES). In adults with bipolar disorder, olanzapine worsened HbA1c/TC/WG (moderate/large ES); asenapine increased fasting glucose (small ES); quetiapine/cariprazine/risperidone induced WG (small/moderate ES). In bipolar depression, lurasidone was metabolically neutral. In depression, psychological interventions improved physical health-related quality of life (PHQoL) (small ES), fasting glucose/HbA1c (medium/large ES); SSRIs improved fasting glucose/HbA1c, readmission for coronary disease, pain (small ES); quetiapine/aripiprazole/olanzapine induced WG (small to large ES). Exercise improved cardiorespiratory fitness (moderate ES). In the elderly, fluoxetine yielded more detrimental cardiovascular effects than sertraline/escitalopram (large ES); antidepressants were neutral on exercise tolerance and PHQoL. In mixed age groups, in bipolar disorder aripiprazole was metabolically neutral; in depression, SSRIs lowered blood pressure versus placebo and serotonin-noradrenaline reuptake inhibitors (small ES); brexpiprazole augmentation caused WG and was less tolerated (small ES); exercise improved PHQoL (moderate ES). Conclusions: Some interventions (psychological therapies, exercise and SSRIs) improve certain physical health outcomes in mood disorders, few are neutral, but various pharmacological interventions are associated with negative effects. Evidence from this umbrella review has limitations, should consider evidence from other disorders and should be integrated with recent evidence from individual RCTs, and observational evidence. Effective treatments with either beneficial or physically neutral profiles should be prioritized.
369-390
Croatto, Giovanni
2b0f321a-25df-457a-9f6b-776e4ae9e319
Vancampfort, Davy
07cb7d49-101e-4979-96a9-bf5e0ce19ead
Miola, Alessandro
1966d43f-01ef-4fc3-8040-d0ccb54f498a
Olivola, Miriam
817ebfca-dfe8-4fc4-a402-f67b6c783a6f
Fiedorowicz, Jess G.
b15b0574-b8ea-4afb-99f0-917e57ea616d
Firth, Joseph
dfdf5916-aca9-4d41-8c79-c0e910cdeba7
Alexinschi, Ovidiu
bc864476-cf87-47d8-9c90-53f261dc566a
Gaina, Marcel A.
a33cf434-f88b-456b-bb71-d4f1759611d6
Makkai, Vladimir
ba38436c-2db9-4d6b-aa2a-d3645938f6bd
Soares, Fernanda Cunha
681939a0-2b0a-4c44-8b88-ce17d85e513b
Cavaliere, Leandro
cd67c976-a2de-4634-8ea1-7cb300ae9225
Vianello, Giorgia
cefcb73f-de3c-4747-bcfb-4d879608597a
Stubbs, Brendon
1b1916f6-b2f8-4257-84de-0c7072c4c67a
Fusar-poli, Paolo
a1ac1bbb-1ffd-4078-98df-d7918650bd2c
Carvalho, Andre F.
faaf51e6-a92a-485b-9d9b-f29590430a3d
Vieta, Eduard
278d5918-f513-47dc-94a3-da918d05e24b
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Shin, Jae Il
cc12b7c4-5ec5-4903-a6de-9d1cb61dabde
Correll, Christoph U.
d1a6c4a7-3911-4ffb-9d9d-4d70f6b574b1
Solmi, Marco
256504f2-483a-4b42-bfab-081c6a617867
January 2023
Croatto, Giovanni
2b0f321a-25df-457a-9f6b-776e4ae9e319
Vancampfort, Davy
07cb7d49-101e-4979-96a9-bf5e0ce19ead
Miola, Alessandro
1966d43f-01ef-4fc3-8040-d0ccb54f498a
Olivola, Miriam
817ebfca-dfe8-4fc4-a402-f67b6c783a6f
Fiedorowicz, Jess G.
b15b0574-b8ea-4afb-99f0-917e57ea616d
Firth, Joseph
dfdf5916-aca9-4d41-8c79-c0e910cdeba7
Alexinschi, Ovidiu
bc864476-cf87-47d8-9c90-53f261dc566a
Gaina, Marcel A.
a33cf434-f88b-456b-bb71-d4f1759611d6
Makkai, Vladimir
ba38436c-2db9-4d6b-aa2a-d3645938f6bd
Soares, Fernanda Cunha
681939a0-2b0a-4c44-8b88-ce17d85e513b
Cavaliere, Leandro
cd67c976-a2de-4634-8ea1-7cb300ae9225
Vianello, Giorgia
cefcb73f-de3c-4747-bcfb-4d879608597a
Stubbs, Brendon
1b1916f6-b2f8-4257-84de-0c7072c4c67a
Fusar-poli, Paolo
a1ac1bbb-1ffd-4078-98df-d7918650bd2c
Carvalho, Andre F.
faaf51e6-a92a-485b-9d9b-f29590430a3d
Vieta, Eduard
278d5918-f513-47dc-94a3-da918d05e24b
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Shin, Jae Il
cc12b7c4-5ec5-4903-a6de-9d1cb61dabde
Correll, Christoph U.
d1a6c4a7-3911-4ffb-9d9d-4d70f6b574b1
Solmi, Marco
256504f2-483a-4b42-bfab-081c6a617867
Croatto, Giovanni, Vancampfort, Davy, Miola, Alessandro, Olivola, Miriam, Fiedorowicz, Jess G., Firth, Joseph, Alexinschi, Ovidiu, Gaina, Marcel A., Makkai, Vladimir, Soares, Fernanda Cunha, Cavaliere, Leandro, Vianello, Giorgia, Stubbs, Brendon, Fusar-poli, Paolo, Carvalho, Andre F., Vieta, Eduard, Cortese, Samuele, Shin, Jae Il, Correll, Christoph U. and Solmi, Marco
(2023)
The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials.
Molecular Psychiatry, 28 (1), .
(doi:10.1038/s41380-022-01770-w).
Abstract
Objective: People with mood disorders have increased risk of comorbid medical diseases versus the general population. It is paramount to identify interventions to improve physical health in this population. Methods: Umbrella review of meta-analyses of randomised controlled trials (RCTs) on pharmacological/non-pharmacological interventions for physical health outcomes/intolerability-related discontinuation in mood disorders (any age). Results: Ninety-seven meta-analyses were included. Among youths, against placebo, in depression, antidepressants/antipsychotics had higher discontinuation rates; in bipolar depression, olanzapine+fluoxetine worsened total cholesterol (TC)/triglycerides/weight gain (WG) (large ES). In adults with bipolar disorder, olanzapine worsened HbA1c/TC/WG (moderate/large ES); asenapine increased fasting glucose (small ES); quetiapine/cariprazine/risperidone induced WG (small/moderate ES). In bipolar depression, lurasidone was metabolically neutral. In depression, psychological interventions improved physical health-related quality of life (PHQoL) (small ES), fasting glucose/HbA1c (medium/large ES); SSRIs improved fasting glucose/HbA1c, readmission for coronary disease, pain (small ES); quetiapine/aripiprazole/olanzapine induced WG (small to large ES). Exercise improved cardiorespiratory fitness (moderate ES). In the elderly, fluoxetine yielded more detrimental cardiovascular effects than sertraline/escitalopram (large ES); antidepressants were neutral on exercise tolerance and PHQoL. In mixed age groups, in bipolar disorder aripiprazole was metabolically neutral; in depression, SSRIs lowered blood pressure versus placebo and serotonin-noradrenaline reuptake inhibitors (small ES); brexpiprazole augmentation caused WG and was less tolerated (small ES); exercise improved PHQoL (moderate ES). Conclusions: Some interventions (psychological therapies, exercise and SSRIs) improve certain physical health outcomes in mood disorders, few are neutral, but various pharmacological interventions are associated with negative effects. Evidence from this umbrella review has limitations, should consider evidence from other disorders and should be integrated with recent evidence from individual RCTs, and observational evidence. Effective treatments with either beneficial or physically neutral profiles should be prioritized.
Text
GC_Physical Health MD_Manuscript_MolPsy_02june22
- Accepted Manuscript
Text
PhysicalHealthMDUR_supmat_MolPsy_23Jan22
- Accepted Manuscript
More information
Accepted/In Press date: 26 August 2022
e-pub ahead of print date: 22 September 2022
Published date: January 2023
Additional Information:
Funding Information:
Dr. Firth is supported by a University of Manchester Presidential Fellowship (P123958) and a UK Research and Innovation Future Leaders Fellowship (MR/T021780/1).
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
Identifiers
Local EPrints ID: 471085
URI: http://eprints.soton.ac.uk/id/eprint/471085
ISSN: 1359-4184
PURE UUID: cd525486-ca48-4f7c-888a-16e71064cc2b
Catalogue record
Date deposited: 25 Oct 2022 16:42
Last modified: 17 Mar 2024 07:33
Export record
Altmetrics
Contributors
Author:
Giovanni Croatto
Author:
Davy Vancampfort
Author:
Alessandro Miola
Author:
Miriam Olivola
Author:
Jess G. Fiedorowicz
Author:
Joseph Firth
Author:
Ovidiu Alexinschi
Author:
Marcel A. Gaina
Author:
Vladimir Makkai
Author:
Fernanda Cunha Soares
Author:
Leandro Cavaliere
Author:
Giorgia Vianello
Author:
Brendon Stubbs
Author:
Paolo Fusar-poli
Author:
Andre F. Carvalho
Author:
Eduard Vieta
Author:
Jae Il Shin
Author:
Christoph U. Correll
Author:
Marco Solmi
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
